Skip to content

ECCO2R - Mechanical Power Study

The Effects of Low Flow Extracorporeal CO2 Removal on Mechanical Power in ARDS Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03939260
Enrollment
15
Registered
2019-05-06
Start date
2019-03-20
Completion date
2024-03-31
Last updated
2019-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS, Human, Extracorporeal CO2 Removal, Mechanical Power

Brief summary

Although mechanical ventilation remains the cornerstone of ARDS treatment, several experimental and clinical studies have undoubtedly demonstrated that it can contribute to high mortality through the developing of ventilator induced lung injury even in patients with plateau pressure \<30 cmH2O. Since now there are no studies exploring the application of low flow extracorporeal CO2 removal and ultraprotective ventilation to reduce mechanical power, a composite index of VILI, independently from the value of plateau pressure or the severity of hypercapnia.

Interventions

OTHERExtracorporeal CO2 Removal

Extracorporeal carbon dioxide removal (ECCO2R), a low flow extracorporeal CO2 removal, may be used in association with ultraprotective mechanical ventilation (tidal volume \< 6 ml/kg and Pplat \<20-25 cmH2O).

Sponsors

University of Milan
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

ARDS patients undergoing mechanical ventilation with: * PaO2/FiO2 \<150 with a level of positive end expiratory pressure (PEEP) of 10 cmH2O or higher with a FiO2 \> 0.5 * Plateau pressure of 28 cmH2O or higher with tidal volume of 6 ml/Kg of ideal body weight * Mechanical power of 18 J/min or higher.

Exclusion criteria

* \<18 years of age * Pregnancy * Obesity with BMI\> 30 * Platelets \<30 G/l * Decompensated heart failure or acute coronary syndrome * Acute brain injury * Contraindication for systemic anticoagulation (for example, gastrointestinal bleeding, recent cerebrovascular accident, or chronic bleeding disorder, recent major surgery) * Patient moribund, decision to limit therapeutic interventions * Catheter access to femoral vein or jugular vein impossible * Pneumothorax.

Design outcomes

Primary

MeasureTime frameDescription
Mechanical Power reduction.Changes from baseline to day 5.Achievement of Mechanical Power reduction under 18 J/min while maintaining pH and PaCO2 to ± 20% of baseline values obtained at tidal volume of 6 mL/kg. Mechanical Power (MP) (J/min) = 0.098 \* respiratory rate \* tidal volume (inspiratory peak airway pressure - 1/2 \* (airway pressure at end inspiratory pause - airway pressure at PEEP))

Secondary

MeasureTime frameDescription
Respiratory mechanics.Every six hours, every day until the fifth day or until the weaning from ECCO2R if lower than five days1\. Respiratory system elastance (Ers) (cmH2O/L) = (airway pressure at end inspiratory pause - airway pressure at PEEP) / tidal volume
Gas exchange.Every six hours, every day until the fifth day or until the weaning from ECCO2R if lower than five daysAssessment of changes in PaCO2 mmHg.
Safety assessment and adverse device related events: frequency of serious adverse eventsEvery day, until the fifth day or until the weaning from ECCO2R if lower than five daysSafety assessment reporting frequency of serious adverse events in terms of device related mechanical events (Pump malfunction, membrane lung clotting, system leaks, tubing rupture, air in the circuit) and device related clinical events (heamolysis, significant bleeding, thromboembolic complications, neurologic complications, metabolic complications).

Countries

Italy

Contacts

Primary ContactDavide Chiumello, Professor
chiumello@libero.it+390281844020

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026